Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313382815> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4313382815 endingPage "70.2" @default.
- W4313382815 startingPage "70.2" @default.
- W4313382815 abstract "Abstract T2 is a lymphoma-derived cell line that express low amounts of HLA-A2 on the cell surface due to TAP deficiency and can only present exogenous peptides. Binding of exogenous peptides to HLA-A2 stabilizes the HLA-A2- peptide complexes and can be detected using immunofluorescence staining. The T2 cell line is commonly used for identification and analysis of novel HLA-A2-restricted CTL epitopes in the assay known as T2 shift. In this study we evaluated parameters that may influence the T2 shift assay performance and considered new applications of this method for testing of the biological activity of peptide-based immunotherapies. Method optimization was performed using HLA-A2-restricted peptide SurA2.M alone and in the context of a peptide-based immunotherapy drug, DPX-Survivac. DPX-Survivac is a lipid nanoparticle-based formulation that contains five peptides aiming to elicit a CTL response against tumor cells presenting the survivin peptides on HLA class I molecules. Results indicated that performance of the T2 shift assay was highly sensitive to cell passaging intervals, pH variations, cell concentrations and β2-microglobulin concentrations. Discrimination of the T2 cells by either size or granularity did not affect the results for the T2 shift assay. We determined the linear response range for the SurA2.M peptide to be 30-110 μg/mL in the T2 shift assay. The T2 shift assay can detect SurA2.M within the DPX-Survivac matrix. In conclusion, we found that optimal culturing conditions of T2 cells are critical for the T2 shift assay reproducibility and linearity and should be carefully considered if the assay is to be used for quantitative or semi-quantitative evaluation of the peptide activity alone or as a part of an immunotherapeutic drug." @default.
- W4313382815 created "2023-01-06" @default.
- W4313382815 creator A5049643528 @default.
- W4313382815 creator A5075562710 @default.
- W4313382815 creator A5088104084 @default.
- W4313382815 date "2019-05-01" @default.
- W4313382815 modified "2023-10-17" @default.
- W4313382815 title "Optimization of the T2 HLA-A2 shift assay for testing of the biological activity of immunotherapies" @default.
- W4313382815 doi "https://doi.org/10.4049/jimmunol.202.supp.70.2" @default.
- W4313382815 hasPublicationYear "2019" @default.
- W4313382815 type Work @default.
- W4313382815 citedByCount "1" @default.
- W4313382815 countsByYear W43133828152021 @default.
- W4313382815 crossrefType "journal-article" @default.
- W4313382815 hasAuthorship W4313382815A5049643528 @default.
- W4313382815 hasAuthorship W4313382815A5075562710 @default.
- W4313382815 hasAuthorship W4313382815A5088104084 @default.
- W4313382815 hasConcept C147483822 @default.
- W4313382815 hasConcept C147969180 @default.
- W4313382815 hasConcept C151730666 @default.
- W4313382815 hasConcept C153911025 @default.
- W4313382815 hasConcept C154317977 @default.
- W4313382815 hasConcept C185592680 @default.
- W4313382815 hasConcept C188280979 @default.
- W4313382815 hasConcept C195616568 @default.
- W4313382815 hasConcept C202751555 @default.
- W4313382815 hasConcept C203014093 @default.
- W4313382815 hasConcept C2779281246 @default.
- W4313382815 hasConcept C2779343474 @default.
- W4313382815 hasConcept C54355233 @default.
- W4313382815 hasConcept C55493867 @default.
- W4313382815 hasConcept C81885089 @default.
- W4313382815 hasConcept C86803240 @default.
- W4313382815 hasConceptScore W4313382815C147483822 @default.
- W4313382815 hasConceptScore W4313382815C147969180 @default.
- W4313382815 hasConceptScore W4313382815C151730666 @default.
- W4313382815 hasConceptScore W4313382815C153911025 @default.
- W4313382815 hasConceptScore W4313382815C154317977 @default.
- W4313382815 hasConceptScore W4313382815C185592680 @default.
- W4313382815 hasConceptScore W4313382815C188280979 @default.
- W4313382815 hasConceptScore W4313382815C195616568 @default.
- W4313382815 hasConceptScore W4313382815C202751555 @default.
- W4313382815 hasConceptScore W4313382815C203014093 @default.
- W4313382815 hasConceptScore W4313382815C2779281246 @default.
- W4313382815 hasConceptScore W4313382815C2779343474 @default.
- W4313382815 hasConceptScore W4313382815C54355233 @default.
- W4313382815 hasConceptScore W4313382815C55493867 @default.
- W4313382815 hasConceptScore W4313382815C81885089 @default.
- W4313382815 hasConceptScore W4313382815C86803240 @default.
- W4313382815 hasIssue "1_Supplement" @default.
- W4313382815 hasLocation W43133828151 @default.
- W4313382815 hasOpenAccess W4313382815 @default.
- W4313382815 hasPrimaryLocation W43133828151 @default.
- W4313382815 hasRelatedWork W1513096311 @default.
- W4313382815 hasRelatedWork W1664174075 @default.
- W4313382815 hasRelatedWork W1998419826 @default.
- W4313382815 hasRelatedWork W2016031396 @default.
- W4313382815 hasRelatedWork W2042955728 @default.
- W4313382815 hasRelatedWork W2052483994 @default.
- W4313382815 hasRelatedWork W2053103268 @default.
- W4313382815 hasRelatedWork W2058710260 @default.
- W4313382815 hasRelatedWork W2372826417 @default.
- W4313382815 hasRelatedWork W3030900991 @default.
- W4313382815 hasVolume "202" @default.
- W4313382815 isParatext "false" @default.
- W4313382815 isRetracted "false" @default.
- W4313382815 workType "article" @default.